Xavier Paolettí - Concepedia

Author

Xavier Paolettí

Also Known As

Gaelle Nachbaur, Institut Curie COVID Group,, Isabelle Ray-Coquard, Knut Nygaard, Koji Oba, Laurence Bozec, Paoletti, Xavier, X Paoletti, X. PAOLETTI, X. Paoletti

298

Publications

8.4K

Citations

H-Index

128

Concepts

All Affiliations

Inserm Institut Curie Institut Gustave Roussy Université de Versailles Saint-Quentin-en-Yvelines Centre de recherche en Epidémiologie et Santé des Populations

About

Xavier Paolettí is an author at Inserm specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	43	4K
2	Health Sciences	13	15	741
3	Public Health	4	4	288
4	Engineering	2	2	108
5	Education	1	1	92

Xavier Paolettí

Publications

5.7K

Citations

H-Index

Page 1

	Year	Citations
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial Christophe Le Tourneau, Jean-Pierre Delord, Anthony Gonçalvès, The Lancet Oncology Advanced CancerDrug TargetingOncologyMedicineVersus Conventional Therapy	2015	1.1K
Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma Esma Saâda-Bouzid, Cécile Defaucheux, Andy Karabajakian, Annals of Oncology OncologyNeoadjuvant TherapyAnti-pd-1/pd-l1 TherapyImmune Checkpoint InhibitorHead And Neck Cancer	2017	596
EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype Sandra Rebouissou, Isabelle Bernard‐Pierrot, Aurélien de Reyniès, Science Translational Medicine Muscle-invasive Bladder CarcinomaPathologyCancer BiologyTumor BiologyOncology	2014	380
Emergency circulatory support in refractory cardiogenic shock patients in remote institutions: a pilot study (the cardiac-RESCUE program) Sylvain Beurtheret, Pierre Mordant, Xavier Paolettí, European Heart Journal	2012	270
Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19) Astrid Lièvre, Anthony Turpin, Isabelle Ray‐Coquard, European Journal of Cancer Solid Cancer PatientsCancer EpidemiologyDisease Risk AssessmentMedicineEpidemiology Of Cancer	2020	163
Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors Birgit Geoerger, Darren Hargrave, Fabienne Thomas, Neuro-Oncology	2010	155
Successful long-term program for controlling methicillin-resistant Staphylococcus aureus in intensive care units Jean‐Christophe Lucet, Xavier Paolettí, Isabelle Lolom, Intensive Care Medicine Intensive Care UnitsMethicillin-resistant Staphylococcus AureusHealth SciencesAntimicrobial SusceptibilityHealthcare-associated Infection	2005	145
Phase I Trials of Molecularly Targeted Agents: Should We Pay More Attention to Late Toxicities? Sophie Postel‐Vinay, Carlos Gomez‐Roca, L Rhoda Molife, Journal of Clinical Oncology	2011	137
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents – Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study Sophie Postel‐Vinay, Laurence Collette, Xavier Paolettí, European Journal of Cancer Therapeutic Drug MonitoringMedicinePharmacologyClinical TrialsToxicology	2014	120
Leukocyte activation: The link between inflammation and coagulation during heatstroke. A study of patients during the 2003 heat wave in Paris* Marie‐Geneviève Huisse, Sébastian Pease, Margarita Hurtado-Nédelec, Critical Care Medicine	2008	117

Page 1